CHMP recommends Zontivity for treatment of Atherothrombotic Events in adult patients with a history of Myocardial Infarction - Merck Inc.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Zontivity, 2 mg, film-coated tablet, from Merck Inc., intended for the reduction of Atherothrombotic Events in adult patients with a history of Myocardial Infarction (MI).
Zontivity should be co-administered with acetylsalicylic acid (ASA) and, where appropriate with clopidogrel. The active substance of Zontivity is vorapaxar a selective and reversible inhibitor of the Protease Activated Receptor-1 present on platelets that are activated by thrombin. The benefits with Zontivity are its ability to inhibit thrombin-induced platelet aggregation in vitro and inhibit thrombin receptor agonist peptide (TRAP)-induced platelet aggregation without affecting coagulation parameters.Vorapaxar does not inhibit platelet aggregation induced by other agonists such as adenosine diphosphate (ADP), collagen or a thromboxane mimetic.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins